LIFR Inhibition Enhances the Therapeutic Efficacy of HDAC Inhibitors in Triple Negative Breast Cancer

Investigators showed that first-in-class Leukemia Inhibitory Factor Receptor (LIFRα) inhibitor EC359 could enhance the therapeutic efficacy of histone deacetylase inhibitors (HDACi) against TNBC.